Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment

CXCR1 and CXCR2 chemokine receptors and their ligands (CXCL1/2/3/7/8) play an important role in tumor progression. Tested to date CXCR1/2 antagonists and chemokine-targeted antibodies were reported to affect malignant cells in vitro and in animal models. Yet, redundancy of chemotactic signals and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemp, Daria Marley, Pidich, Alyson, Larijani, Mary, Jonas, Rebecca, Lash, Elizabeth, Sato, Takami, Terai, Mizue, Pizzol, Maria De, Allegretti, Marcello, Igoucheva, Olga, Alexeev, Vitali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362416/
https://www.ncbi.nlm.nih.gov/pubmed/28129639
http://dx.doi.org/10.18632/oncotarget.14803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362416/
https://www.ncbi.nlm.nih.gov/pubmed/28129639
http://dx.doi.org/10.18632/oncotarget.14803

Ejemplares similares